Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Greg Kennelty
Advertisement
Articles by Greg Kennelty
Lenalidomide (Revlimid) was found to significantly increase progression-free survival in patients with relapsed/refractory mantle cell lymphoma when compared with investigator's choice of single-agent therapy.
Advertisement
Latest Updated Articles
Lenalidomide Delays Progression in Mantle Cell LymphomaPublished: March 29th 2016 | Updated:
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCCPublished: May 11th 2016 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
3
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
4
